Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany.
BACKGROUND
The study objective was to detect any incidence of aseptic meningitis associated with measles-mumps-rubella (MMR) vaccines that would be considered of public health importance subsequent to the introduction of a new MMR vaccine (Priorix).


METHODS
Adverse drug reaction (ADR) rates were calculated by relating the number of cases to the number of doses of the different MMR vaccines distributed during a 2-year period in Germany.


RESULTS
During the 2-year study period 1,575,936 doses of Priorix and 1,907,875 doses of other MMR vaccines were distributed in Germany. There were no confirmed cases of aseptic meningitis associated with MMR vaccination during this period. Thus, the ADR rates (rejectable with 5% alpha error) were lower than 1/525,312 for Priorix and lower than 1/635,958 for other MMR vaccines.


CONCLUSIONS
The safety profile of the Priorix is similar to that of other MMR vaccines used in Germany.
Schlipköter
U
U
Institute for Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilian University, Marchioninistr. 15, D-81377 Munich, Germany. schli@ibe.med.uni-muenchen.de
Mühlberger
N
N
von Kries
R
R
Weil
J
J
D002648:Child; D002675:Child, Preschool; D006801:Humans; D022542:Measles-Mumps-Rubella Vaccine / Q000009:adverse effects*; D008582:Meningitis, Aseptic / Q000209:etiology*
D022542:Measles-Mumps-Rubella Vaccine